title: Patient characteristics related to metabolic disorders and chronic complications in type 2 diabetes mellitus patients hospitalized at the Qingdao Endocrine and Diabetes Hospital from 2006 to 2012 in China.
abstract: To study the clinical characteristics related to metabolic disorders and complications in type 2 diabetes mellitus patients hospitalized in the Qingdao Endocrine and Diabetes Hospital from 2006 to 2012 in Qingdao, China.
  
  
  
  Data from 14,289 (51% males) type 2 diabetes mellitus patients hospitalized between 2006 and 2012 were collected and analysed. Information on patients' demographic, anthropometric, laboratory and disease histories were extracted from electronic medical records.
  
  
  
  The mean age of the patients was 60.5 years, with median diabetes duration of 9.0 years. Mean haemoglobin A1c was 8.4%, where <30.0% of patients had haemoglobin A1c <7.0%. In all, 34.5% of patients had low-density lipoprotein cholesterol lower than 2.6 mmol/L and 31.9% had hypertriglyceridaemia. Retinopathy was diagnosed in 51.1% of patients, nephropathy in 21.6%, neuropathy in 50.4%, hypertension in 77.4%, coronary heart disease in 27.6% and peripheral vascular disease in 58.6%. Once hospitalized, 71.1% of patients underwent insulin injection treatments, either mono-therapy or combined with other anti-diabetic drugs. Metformin was prescribed to 36.9% of patients, followed by acarbose 29.9%, thiazolidinediones 18.1%, meglitinides 14.8% and sulfonylureas 10.7%.
  
  
  
  Inadequate control of hyperglycaemia, poor metabolic profiles and diabetic complications were common challenges for long-term diabetes management in Chinese patients with type 2 diabetes mellitus.
authors.affiliation: Qingdao Endocrine and Diabetes Hospital, Qingdao, China.
authors.forename: Yanhu
authors.initials: Y
authors.lastname: Dong
authors.affiliation: R & D Information China, AstraZeneca, Shanghai, China gwg1974@hotmail.com.
authors.forename: Weiguo
authors.initials: W
authors.lastname: Gao
authors.affiliation: Qingdao Endocrine and Diabetes Hospital, Qingdao, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.affiliation: R & D Information China, AstraZeneca, Shanghai, China.
authors.forename: Jia
authors.initials: J
authors.lastname: Wei
authors.affiliation: Medical Evidence & Observational Research Centre, Global Medicines Development, AstraZeneca R&D, Mölndal, Sweden.|Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Niklas
authors.initials: N
authors.lastname: Hammar
authors.affiliation: Global Medicines Development, AstraZeneca R&D, Mölndal, Sweden.
authors.forename: Claudia S
authors.initials: CS
authors.lastname: Cabrera
authors.affiliation: Qingdao Endocrine and Diabetes Hospital, Qingdao, China.
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Wu
authors.affiliation: Medical Evidence & Observational Research Centre, Global Medicines Development, AstraZeneca R&D, Mölndal, Sweden.|Department of Public Health, University of Helsinki, Helsinki, Finland.
authors.forename: Qing
authors.initials: Q
authors.lastname: Qiao
mesh_terms: D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002681:China / Q000453:epidemiology; D015897:Comorbidity; D048909:Diabetes Complications / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D057286:Electronic Health Records; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006761:Hospitals; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012307:Risk Factors; D013997:Time Factors
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D008055:Lipids; C517652:hemoglobin A1c protein, human
keywords: Type 2 diabetes mellitus; anti-hyperglycaemia treatment pattern; diabetic complication; metabolic control